

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Yatscoff et al.  
Serial No.: Unknown  
Filed: Herewith  
Title: "A METHOD FOR PRODUCTION OF ANTIBODIES TO SPECIFIC  
SITES OF RAPAMYCIN"  
Docket No.: 826

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references listed on the attached PTO Form-1449. A copy of the references was previously submitted or cited in the parent application Serial No. 09/638,900, filed on August 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Therefore, according to 37 C.F.R. § 1.98(d), a copy of the cited references is not required, and is not included herewith.

January 13, 2004  
Date

Respectfully submitted,

Susan Sutterfield Wilks  
Susan Sutterfield Wilks, Reg. No. 48,192  
Associate General Counsel  
ISOTECHNIKA INC.  
17301 North Perimeter Drive  
Suite 100  
Scottsdale, AZ 85255  
Telephone: (480)-505-0540 Ext. 3213  
Fax: (480)-505-0545

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL, Express Mail Label #ER072746018US, in an envelope addressed to MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 13, 2004.

Date: 1/13/04

Pamela A. Matheis  
Pamela A. Matheis

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.

826

APPLICATION NO.

New

APPLICANT

Randall W. Yatscoff, et al.

FILING DATE

Herewith

GROUP

Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,441,977	08/15/95	Russo et al.			
	5,322,772	06/21/94	Soldin			
	4,981,792	01/01/91	Inamine et al.			
	5,270,187	12/14/93	Chen et al.			
	5,202,258	04/13/93	Chen et al.			
	5,504,091	04/02/96	Molnar-Kimber et al.			
	5,268,370	12/07/93	Arison et al.			
	5,635,406	06/03/97	Grenier et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	WO 94/25022	11/10/94	PCT				
	WO 93/25533	12/23/93	PCT				
	WO 94/24304	10/27/94	PCT				
	WO 94/25072	11/10/94	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abraham R.T., "Mammalian Target of Rapamycin: Immunosuppressive Drugs Uncover a Novel Pathway of Cytokine Receptor Signaling," <i>Curr. Opin. Immunol.</i> , June 1998; 10(3):330-336.
	Blazar B.R., Taylor, P. A., Panoskaltsis-Mortari A., Valleria D.A., "Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines," <i>J. Immunol.</i> , June 1, 1998; 160(11): 5355-5365.
	Brunn, G.J., Fadden, P., Haystead, T.A.J., Lawrence, J. C., Jr., "The Mammalian Target of Rapamycin Phosphorylates Sites Having a (Ser/thr)-pro Motif and Is Activated by Antibodies to a Region near its COOH Terminus," <i>J. Biol. Chem.</i> , December 19, 1997; 272(51): 32547-32550.
	Christians U., Sattler M., Schiebel, H. M., Kruse C., Radeke H.H., Linck A., Sewing K-FR, "Isolation of Two Immunosuppressive Metabolites after in Vitro Metabolism of Rapamycin," <i>Drug Met and Disp.</i> , 1992; 20(2)186-191.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTORNEY'S DKT NO. <b>826</b>		APPLICATION NO. New	
				APPLICANT Randall W. Yatscoff, et al.			
				FILING DATE Herewith		GROUP Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,604,092	02/18/97	Erlanger et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes    No	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Donnelly J. G., Soldin S.J., "Partial Characterization of a 52 kDa CsA/FK506/Rapamycin Binding Protein," <i>Clin Biochem.</i> , Oct. 1994; 27 (4):367-372.						
	Hale D. A., Gottschalk R., Fukuzaki T., Wood M.L., Maki, T., Monaco A.P., "Superiority of Sirolimus (Rapamycin) over Cyclosporine in Augmenting Allograft and Xenograft Survival in Mice Treated with Antilymphocyte Serum and Donor-specific Bone Marrow," <i>Transplantation</i> , Feb. 15, 1997; 63(3):359-364.						
	Hale, D.A., Gottschalk R., Maki T., Monaco A. P., "Determination of an Improved Sirolimus (Rapamycin)-based Regimen for Induction of Allograft Tolerance in Mice Treated with Antilymphocyte Serum and Donor-specific Bone Marrow," <i>Transplantation</i> , Feb. 27, 1998; 65(4):473-479.						
	Hashemolhosseini S., Nagamine Y., Morley S. J., Desrivieres S., Mercep L., Ferrari S., "Rapamycin Inhibition of the G1 to S Transition is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," <i>J. Biol. Chem.</i> , June 5, 1998; 273(23): 14424-14429.						
	Kawasone H., Papst P., Webb S., Keller G.M., Johnson G. L., Gelfand E. W., Terada N., "Targeted Disruption of p70(s6k) Defines its Role in Protein Synthesis and Rapamycin Sensitivity," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , April 28, 1998; 95(9):5033-5038.						
	Luengo J.L., Yamashita D.S., Dunnington D., Konialian Beck A., Rozamus L.W., Yen H.K., Bossard M. J., Levy M.A., Hand, A., Newman-Tarr T., Badger A., Faucette L., Johnson R. K., D'Alessio K., Porter T., Shu, A.Y.L., Heys R., Choi J., Kongsaree P., Clardy J., Holt D.A., "Structure-activity Studies of Rapamycin Analogs: Evidence That the C-7 Methoxy Group is Part of the Effector Domain and Positioned at the FKBP12-FRAP Interface," <i>Chem. and Biol.</i> , July 1995; 2:471-481.						
	Makrigiannis A.P., Hoskin D.W., "Inhibition of CTL Induction by Rapamycin: IL-2 Rescues Granzyme B and Perforin Expression but Only Partially Restores Cytotoxic Activity," <i>J. Immunol.</i> , Nov. 15, 1997; 159(10):4700-4707.						
	Napoli K.L., Kahan B.D., "Routine Clinical Monitoring of Sirolimus (Rapamycin) Whole-blood Concentrations by HPLC with Ultraviolet Detection," <i>Clin. Chem.</i> , Dec. 1996; 42(12):1943-1948.						
	Nickmilder M.J.M., Latinne D., Verbeeck R.K., Janssens W., Svoboda D., Lhoest G.J.J., "Isolation and Identification of New Rapamycin Dihydrodiol Metabolites from Dexamethasone-induced Rat Liver Microsomes," <i>Xenobiotica</i> , 1997; 27(9):869-883.						
	Schuler W., Sedrani R., Cottens S., Haberin B., Schulz M., Schuurman H.J., Zenke G., Zerwes H.G., Schreier M.H., "SDZ RAD, a New Rapamycin Derivative; Pharmacological Properties in Vitro and In Vivo," <i>Transplantation</i> , July 15, 1997; 64(1):36-42.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.

826

APPLICATION NO.

New

APPLICANT

Randall W. Yatscoff, et al.

FILING DATE

Herewith

GROUP

Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
------------------------	------------	------	------	-------	----------	-------------

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No
------------------------	------------	------	---------	-------	----------	-----------------------

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Schuurman H., Cottens S., Fuchs S., Joergensen J., Meerloo T., Sedrani R., Tanner M., Zenke G., Schuler W., "SDZ RAD, a New Rapamycin Derivative; Synergism with Cyclosporine," *Transplantation*, July 15, 1997; 64(1):32-35.

Streit F., Christians U., Shiebel H.M., Meyer A., Sewing K.F., "Structural Identification of Three Metabolites and a Degradation Product of the Macrolide Immunosuppressant Sirolimus (Rapamycin) by Electrospray-MS/MS after Incubation with Human Liver Microsomes," *Met and Disp.*, 1996; 24(11):1272-1278.

Streit, F., Christians U., Shiebel H.M., Napoli K.L., Ernst L., Linck A., Kahan B. D., Sewing K.F., "Sensitive and Specific Quantification of Sirolimus (Rapamycin) and its Metabolites in Blood of Kidney Graft Recipients by HPLC/Electrospray-Mass Spectrometry," *Clin. Chem.* 1996; 42(9):1417-1425.

Suthanthiran M., Morris R.E., Strom T.B., "Immunosuppressants: Cellular and Molecular Mechanisms of Action," *Am J Kidney Dis*, Aug. 1996, 28(2): 159-17.

Svensson J.O., Brattstrom C., Sawe J., "Determination of Rapamycin in Whole Blood by HPLC," *Ther Drug Monit*, Feb. 1997; 19(1):112-116.

Tsunoda S.M., Aweeka F.T., "The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy," *Clin Pharmacokinet*, Feb. 1996; 30(2):107-140.

Wang M.E., Tejpal N., Qu X., Yu J., Okamoto M., Stepkowski S.M., Kahan B.D. "Immunosuppressive Effects of FTY720 Alone or in Combination with Cyclosporine And/or Sirolimus," *Transplantation*, Apr. 15, 1998; 65(7):899-905.

Weng Q.P., Kozlowske M., Belhan C., Zhang A., Comb M.J., Avruch J., "Regulation of the p70 S6 Kinase by Phosphorylation in Vivo. Analysis Using Site-specific Anti-phosphopeptide Antibodies," *J Biol Chem*, June 26, 1998; 273(26):16621-16629.

Yatscoff R.W., Aspeslet L.J., Gallant H.L., "Pharmacodynamic Monitoring of Immunosuppressive Drugs," *Clin Chem*, 1998; 44(2):428-432.

Yatscoff R.W., Boeckx R., Holt D.W., Kahan B.D., LeGatt D.F., Shegal S., Soldin S.J., Napoli K., Stilel C., "Consensus Guidelines for Therapeutic Drug Monitoring of Rapamycin: Report of the Consensus Panel," *Ther Drug Monit*, 1995; 17:676-680.

Copeland K.R., Yatscoff R.W., "The Isolation, Structural Characterization, and Immunosuppressive Activity of Cyclosporin G (Nva<sup>2</sup>-Cyclosporine) Metabolites," *Ther Drug Monit*, 1991; 13:281-288.

Malcolm A.J., Messner P., Sleytr U.B., Smith R.H., Unger F.M., "Crystalline Bacterial Cell Surface Layers (S-Layers) as Combined Carrier/Adjuvants for Conjugate Vaccines," in *Immobilised Macromolecules: Application Potentials*, Sleytr UB, Messner D, Pum D, Springer-Verlag, 1993; Chapter 13, pp. 195-207.

Kissinger C.R., Parge H.E., Knighton D.R., Lewis C.T., Pelletier L.A., Tempczyk A., Kalish V.J., Tucker K.D., Showalter R.E., Moomaw E.W., Gastinel L.N., Habuka N., Chen X., Maldonado F., Barker J.E., Bacquet R., Villafranca J.E., "Crystal Structures of Human Calcineurin and the Human FKBP12-FK506-Calcineurin Complex," *Nature*, Dec. 7, 1995; 378, 641-684.

EXAMINER

DATE CONSIDERED

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTORNEY'S DKT. NO. 826		APPLICATION NO. New	
				APPLICANT Randall W. Yatscoff, et al.			
				FILING DATE Herewith		GROUP Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Griffith J.P., Kim J.L., Kim E.E., Sintchak M.D., Thomson J.A., Fitzgibbon M.J., Fleming M.A., Caron P.R., Hsiao K., Navia M.A., "X-Ray Structure of Calcineurin Inhibited by the Immunophilin-Immunosuppressant FKB12-FK506 Complex," <i>Cell</i> , Aug. 11, 1995; 82, 507-522.						
	Itoh S., Navia M.A., "Structure comparison of Native and Mutant Human Recombinant FKBP 12 Complexes with the Immunosuppressant Drug FK506 (Tacrolimus)," <i>Protein Science</i> , 1995; 4:2261-2368.						
	Michnick S.W., Rosen M.K., Wandless T.J., Karplus M., Schreiber S.L., "Solution Structure of FKBP, a Rotamase Enzyme and Receptor for FK506 and Rapamycin," <i>Science</i> , May 1991; 252, 836-839.						
	Van Duyne G.D., Standaert R.F., Karplus P.A., Schreiber S.L., Clardy J., "Atomic Structure of FKBP-FK506, an Immunophilin-Immunosuppressant Complex," <i>Science</i> , May 1991; 252, 839-842.						
	Wang C.P., Chan K.W., Schiksnis R.A., Scatina J., Sisenwine S.F., "High Performance Liquid Chromatographic Isolation, Spectroscopic Characterization, and Immunosuppressive activities of Two rapamycin Degradation products," <i>Journal of Liquid Chromatography</i> , 1994; 17(16), 3383-3392.						
	Sattler M., Guengerich F.P., Yun C.H., Christians U., Sewing K.F., "Cytochrome P-450 3A Enzymes Are Responsible for Biotransformation of FK506 and Rapamycin in Man and Rat," <i>Drug Metabolism and Disposition</i> , 1992; 20, (5) 753-761.						
	Dias V.C., Yatscoff R.W., "Investigation of Rapamycin Transport and Uptake Across Absorptive Human Intestinal Cell Monolayers," <i>Clinical Biochemistry</i> , Feb. 1994; (27) 31-36.						
	Sattler M., Geungerich F.P., Christians U., Sewing K.F., "Cytochrome P-450III A4 is Involved in Biotransformation of FK506 and Rapamycin in Rat and Human Liver," <i>Gastroenterology</i> , 102, (4) Part 2, A880.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.